Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Percentage of Participants With Objective Response (OR)

Outcome Description:

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

Outcome Time Frame:

Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4061023

NCT ID:

NCT00282048

Start Date:

March 2006

Completion Date:

June 2009

Related Keywords:

• Kidney Neoplasms
• Carcinoma, Renal Cell
• Neoplasms
• Carcinoma
• Carcinoma, Renal Cell
• Kidney Neoplasms